The Lancet RCT: Semaglutide Reduces Heavy Drinking in Adults With Alcohol Use Disorder

A randomized, double-blind, placebo-controlled trial published this week in The Lancet found that once-weekly semaglutide — the GLP-1 receptor agonist best known as Ozempic and Wegovy — significantly reduced heavy drinking days in adults with alcohol use disorder (AUD) and comorbid obesity, compared to placebo, over a 26-week treatment period. All participants received standard cognitive behavioral therapy (CBT) sessions.

The Trial Design

The study enrolled adults meeting diagnostic criteria for AUD who also had a body mass index consistent with obesity. Participants were randomized to receive weekly subcutaneous semaglutide injections or placebo, while all participants were offered CBT. The primary outcome was reduction in heavy drinking days, defined as days with five or more standard drinks for men and four or more for women.

The 26-week timeframe matches the duration used in semaglutide’s obesity and diabetes trials, allowing direct comparison of adherence and tolerability profiles.

What the Data Showed

NIH confirmed in a companion announcement that GLP-1 therapy meaningfully reduced heavy drinking days beyond what CBT alone achieved. The size of the effect places semaglutide among the strongest pharmacological signals seen in AUD trials — a category where naltrexone and acamprosate, the two existing FDA-approved medications, show modest effects in many populations.

The Biology Behind the Signal

GLP-1 receptors are distributed across brain regions governing satiety, reward, and motivation — the same circuits that underlie addictive behavior toward alcohol, and toward food. Animal models published since 2022 have shown that GLP-1 agonists reduce self-administration of alcohol, cocaine, and nicotine in rodents. Observational studies in humans have linked GLP-1 prescriptions to reduced alcohol use disorder diagnoses, fewer cannabis-related healthcare visits, and lower risk of opioid overdose.

The proposed mechanism: GLP-1 agonism dampens reward salience — the degree to which the brain treats alcohol as a priority target for seeking behavior — without blocking the underlying hedonic capacity entirely. This is biologically distinct from naltrexone, which blocks opioid-mediated reward, and from disulfiram, which creates aversive consequences.

What the Trial Cannot Tell Us

The enrollment criterion of comorbid obesity is a significant constraint. Every participant in the trial had a BMI meeting the obesity threshold. That criterion was necessary — semaglutide is approved for obesity, providing legal and regulatory cover for off-label AUD use — but it means the results cannot yet be generalized to people with AUD who are at healthy weight or underweight, a substantial portion of the population seeking alcohol treatment.

The trial also layered semaglutide on top of CBT, not as a standalone. Whether GLP-1 agonism reduces drinking in people who are not simultaneously receiving behavioral support is unknown.

Why This Matters for People in Recovery

Alcohol kills approximately 105,000 Americans annually — roughly the same toll as drug overdoses at the peak of the opioid crisis — but receives a fraction of the clinical research investment. If semaglutide’s signal holds across broader populations and replication, it could represent the most significant advance in AUD pharmacotherapy in over two decades. It would also arrive at a moment when access to any FDA-approved AUD treatment remains profoundly limited: fewer than 10% of people with AUD receive any pharmacotherapy.

Rize Recovery’s matching tool helps people with alcohol use disorder find treatment programs that include both behavioral and medication-assisted options. Find programs near you.